HWM
HighMark Wealth Management Portfolio holdings
AUM
$205M
1-Year Return
18.44%
This Quarter Return
+3.4%
1 Year Return
+18.44%
3 Year Return
+65.97%
5 Year Return
+111.28%
10 Year Return
–
AUM
$174M
AUM Growth
-$8.76M
(-4.8%)
Cap. Flow
-$11.4M
Cap. Flow
% of AUM
-6.57%
Top 10 Holdings %
Top 10 Hldgs %
74.19%
Holding
634
New
37
Increased
129
Reduced
104
Closed
58
Top Buys
| 1 |
AtriCure
ATRC
|
$413K |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$169K |
| 3 |
Evolent Health
EVH
|
$133K |
| 4 |
Bridger Aerospace
BAER
|
$128K |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
$126K |
Top Sells
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
$1.54M |
| 2 |
iShares S&P 500 Value ETF
IVE
|
$1.45M |
| 3 |
iShares Core US Aggregate Bond ETF
AGG
|
$985K |
| 4 |
iShares Russell 2000 Value ETF
IWN
|
$858K |
| 5 |
iShares Core S&P Mid-Cap ETF
IJH
|
$836K |
Sector Composition
| 1 | Healthcare | 14.36% |
| 2 | Financials | 5.6% |
| 3 | Technology | 4.28% |
| 4 | Industrials | 1.43% |
| 5 | Consumer Discretionary | 1.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
AstraZeneca
AZN
$253B
| $5.16K | ﹤0.01% |
79
| – | – |
|
377
Schwab US Dividend Equity ETF
SCHD
$71.8B
| $5.15K | ﹤0.01% |
189
+3
| +2% | +$82 |
|
378
Huntington Ingalls Industries
HII
$10.6B
| $5.1K | ﹤0.01% |
27
-5
| -16% | -$945 |
|
379
Cboe Global Markets
CBOE
$24.3B
| $5.08K | ﹤0.01% |
26
-5
| -16% | -$977 |
|
|
ELME
380
Elme Communities
ELME
$1.52B
| $5.06K | ﹤0.01% |
332
+4
| +1% | +$61 |
|
381
Leidos
LDOS
$23B
| $5.04K | ﹤0.01% |
+35
| New | +$5.04K |
|
382
Gentex
GNTX
$6.25B
| $5.02K | ﹤0.01% |
175
+1
| +0.6% | +$29 |
|
383
Warner Bros
WBD
$30B
| $4.99K | ﹤0.01% |
472
-103
| -18% | -$1.09K |
|
384
BioMarin Pharmaceuticals
BMRN
$11.1B
| $4.93K | ﹤0.01% |
75
| – | – |
|
385
Novo Nordisk
NVO
$245B
| $4.83K | ﹤0.01% |
56
+8
| +17% | +$690 |
|
386
Martin Marietta Materials
MLM
$37.5B
| $4.65K | ﹤0.01% |
9
| – | – |
|
387
Rithm Capital
RITM
$6.69B
| $4.64K | ﹤0.01% |
429
+6
| +1% | +$65 |
|
388
Ball Corp
BALL
$13.9B
| $4.58K | ﹤0.01% |
83
-9
| -10% | -$496 |
|
389
Omnicell
OMCL
$1.47B
| $4.45K | ﹤0.01% |
100
| – | – |
|
390
Vertex Pharmaceuticals
VRTX
$102B
| $4.43K | ﹤0.01% |
11
| – | – |
|
391
EOG Resources
EOG
$64.4B
| $4.41K | ﹤0.01% |
36
-14
| -28% | -$1.72K |
|
392
Edgewise Therapeutics
EWTX
$1.64B
| $4.41K | ﹤0.01% |
+165
| New | +$4.41K |
|
393
Horizon Kinetics Medical ETF
MEDX
$17.5M
| $4.31K | ﹤0.01% |
165
+3
| +2% | +$78 |
|
394
Maplebear
CART
$11.9B
| $4.14K | ﹤0.01% |
100
| – | – |
|
395
Sutro Biopharma
STRO
$89.9M
| $4.14K | ﹤0.01% |
2,250
| – | – |
|
396
Zymeworks
ZYME
$1.14B
| $4.1K | ﹤0.01% |
280
| – | – |
|
397
Prudential
PUK
$33.7B
| $4.02K | ﹤0.01% |
252
| – | – |
|
398
iShares MSCI India ETF
INDA
$9.26B
| $3.98K | ﹤0.01% |
76
+1
| +1% | +$52 |
|
399
Unilever
UL
$158B
| $3.97K | ﹤0.01% |
70
| – | – |
|
400
EQT Corp
EQT
$32.2B
| $3.69K | ﹤0.01% |
+80
| New | +$3.69K |
|